Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Divyansh K. Mishra
Re: Wells Et Al.: Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results From a Comparative Effectiveness Randomized Clinical Trial (Ophthalmology 2016;123:1351-1359)
Ophthalmology
Ophthalmology
Related publications
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Ophthalmology
Ophthalmology
Comparative Effectiveness Trial for Diabetic Macular Edema
JAMA Ophthalmology
Ophthalmology
Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Ophthalmology
Ophthalmology
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Acta Ophthalmologica
Medicine
Ophthalmology
Re: Das Et Al.: Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets (Ophthalmology 2015;122:1375-94)
Ophthalmology
Ophthalmology
Pss34 - Cost-Effectiveness of Intravitreal Aflibercept Versus Ranibizumab in the Treatment of Diabetic Macular Edema in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema
American Journal of Ophthalmology
Ophthalmology
Re: Feuer Et Al.: Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results (Ophthalmology 2016;123:558-70)
Ophthalmology
Ophthalmology
Cost-Effectiveness of Ranibizumab Versus Aflibercept in the Treatment of Visual Impairment Due to Diabetic Macular Edema: A UK Healthcare Perspective
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
